Companies: 49,244 Total Market Cap: 132622156248962.73

Wave Life Sciences Ltd.

NASDAQ: WVE
Healthcare Biotechnology
Rank #9331
Market Cap 995.71 M
Volume 893,335
Price 6.46
Change (%) 2.05%
Country or region Singapore Singapore

Wave Life Sciences Ltd.'s latest marketcap:

995.71 M

As of 05/20/2025, Wave Life Sciences Ltd.'s market capitalization has reached $995.71 M. According to our data, Wave Life Sciences Ltd. is the 9331th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 995.71 M
Revenue (ttm) 104.94 M
Net Income (ttm) -112,328,000
Shares Out 154.13 M
EPS (ttm) -0.77
Forward PE 0.00
Ex-Dividend Date n/a
Earnings Date 05/08/2025
Market Cap Chart
Data Updated: 05/20/2025

Wave Life Sciences Ltd.'s yearly market capitalization.

Wave Life Sciences Ltd. has seen its market value grow from $383.88 M to $995.71 M since 2020, representing a total increase of 159.38% and an annual compound growth rate (CAGR) of 24.28%.
Date Market Cap Change (%)
05/20/2025 $995.71 M -46.2%
12/31/2024 $1.89 B 213.58%
12/29/2023 $601.65 M -1.1%
12/30/2022 $608.37 M 229.32%
12/31/2021 $184.73 M -51.88%
12/31/2020 $383.88 M

Company Profile

About Wave Life Sciences Ltd.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company focused on designing, developing, and commercializing innovative RNA medicines through its proprietary PRISM platform.

PRISM Platform

The company’s PRISM platform integrates multiple modalities, advanced chemistry, and human genetic insights to create breakthrough treatments for both rare and prevalent disorders.

Key Pipeline Programs

  • WVE-006 – An RNA editing oligonucleotide targeting alpha-1 antitrypsin deficiency.
  • WVE-007 – A GalNAc-conjugated siRNA designed to silence INHBE mRNA for obesity treatment.
  • WVE-N531 – An exon skipping oligonucleotide for Duchenne muscular dystrophy.
  • WVE-003 – An allele-selective oligonucleotide for Huntington’s disease (HD).

Strategic Collaborations

  • GlaxoSmithKline – Research, development, and commercialization of oligonucleotide therapeutics.
  • Takeda Pharmaceutical – CNS disorder-focused oligonucleotide therapeutics.
  • Asuragen, Inc. – Development of companion diagnostics for HD therapeutic programs.

Founded in 2012, Wave Life Sciences Ltd. is headquartered in Singapore.

Frequently Asked Questions

As of 05/20/2025, Wave Life Sciences Ltd. (including the parent company, if applicable) has an estimated market capitalization of $995.71 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Wave Life Sciences Ltd. global market capitalization ranking is approximately 9331 as of 05/20/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region Singapore
Founded 2012
IPO Date 11/11/2015
Employees 288
CEO Paul B. Bolno
Sector Healthcare
Industry Biotechnology
Address Marina One East Tower, 7 Straits View No.12-00
Singapore, 018936
Singapore
Website https://wavelifesciences.com
People Also Watch
VRTX
440.66 2.05%
CSL Limited
156.61 2.05%
REGN
596.54 2.05%
KRX-207940
732.25 2.05%